key: cord-0960597-hn0m69t9
authors: Clancy, Cornelius J; Schwartz, Ilan S; Kula, Brittany; Nguyen, M Hong
title: Bacterial superinfections among persons with coronavirus disease 2019:A comprehensive review of data from postmortem studies
date: 2021-02-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab065
sha: 248b849e4faa8f34755adfb6bd890abf7ca98580
doc_id: 960597
cord_uid: hn0m69t9

BACKGROUND: Limited clinical data suggest ~16% prevalence of bacterial superinfections among critically ill patients with coronavirus disease 2019 (COVID-19). METHODS: We reviewed postmortem studies of patients with COVID-19 published in English through 26 September 2020 for histopathologic findings consistent with bacterial lung infections. RESULTS: Worldwide, 621 patients from 75 studies were included. The quality of data was uneven, likely because identifying superinfections was not a major objective in 96% (72/75) of studies. Histopathology consistent with potential lung superinfection was reported in 32% (200/621) of patients (22-96 years old; 66% men). Types of infections were pneumonia (95%), abscesses or empyema (3.5%), and septic emboli (1.5%). Seventy-three percent of pneumonias were focal rather than diffuse. Predominant histopathologic findings were intra-alveolar neutrophilic infiltrations that were distinct from those typical of COVID-19-associated diffuse alveolar damage. In studies with available data, 79% of patients received antimicrobial treatment; most common agents were beta-lactam/beta-lactamase inhibitors (48%), macrolides (16%), cephalosoprins (12%), and carbapenems (6%). Superinfections were proven by direct visualization or recovery of bacteria in 25.5% (51/200) of potential cases, and 8% of all patients in postmortem studies. In rank order, pathogens included Acinetobacter baumannii, Staphylococcus aureus, Pseudomonas aeruginosa and Klebsiella pneumoniae. Lung superinfections were causes of death in 16% of potential cases, and 3% of all patients with COVID-19. CONCLUSIONS: Potential bacterial lung superinfections were evident at postmortem examination in 32% of persons who died with COVID-19 (proven, 8%; possible, 24%), but they were uncommonly the cause of death.

A c c e p t e d M a n u s c r i p t 5 studies have been published from throughout the world, which have defined diffuse alveolar damage (DAD) as the histopathologic hallmark of severe SARS-CoV-2 infection. [6] The most common cause of death is acute respiratory distress syndrome (ARDS) stemming from DAD, often complicated by cardiopulmonary and other organ failure. [6, 7] To date, postmortem data on infections complicating COVID- 19 have not been collated. We hypothesized that postmortem studies would give insight into the frequency, clinical and microbiologic features, and severity of bacterial superinfections. In this study, we reviewed published reports of persons who died with COVID-19 in whom postmortem histopathologic findings were consistent with bacterial lung infections.

We conducted a PubMed search of papers published in the peer-reviewed, English language literature through 26 September 2020 using terms "coronavirus disease 2019", "COVID-19", "novel coronavirus", "severe acute respiratory syndrome virus coronavirus-2" or "SARS-CoV-2" and "autopsy", "postmortem" or "histopathology."

Studies were considered for inclusion if they presented histopathologic data from postmortem samples of lungs from SARS-CoV-2-infected persons. Papers cited in eligible studies identified by PubMed searches were also reviewed. Cases were included if they described histopathologic findings in the lung that were consistent with bacterial superinfections (see definitions below). An author of this study (CJC and/or ISS) contacted corresponding authors of eligible postmortem studies by e-mail with requests for clarification of published data, as well M a n u s c r i p t 6 as queries about pathogen visualization, and culture and polymerase chain reaction (PCR) results that may not have appeared in the respective publications.

Proven superinfections were defined if bacteria were directly visualized in lung tissue, or detected by culture or PCR in patients for whom histopathologic findings were consistent with superinfection. Culture results described as "mixed flora" or "consistent with postmortem contamination" were excluded. Histopathology consistent with superinfection was defined as: a) descriptions of intra-alveolar and/or peribronchial neutrophilic infiltrates that were distinct from diffuse interstitial and mild intra-alveolar neutrophil accumulations typically seen with DAD; b) intra-alveolar and/or peribronchial neutrophilic infiltrates that were described as distinct from typical findings of proliferative, organizing or fibrotic DAD; c) statements that findings were "consistent with bacterial pneumonia"; or d) direct visualization of bacteria within tissue. [8, 9] Possible superinfection was defined as a case in which histopathology was consistent with superinfection, but bacteria were not visualized in tissue, or detected by culture or PCR. Potential superinfections encompassed both proven and possible superinfections.

From 75 published postmortem studies, we identified 621 patients with COVID-19 for whom descriptions of lung histopathology were provided. Ninety-six percent ( ventilation vs. those who did not; those from different continents (data not shown);

and those presenting in different months.

Lung superinfections were the cause of death of 16% (16/97) of patients with potential bacterial infections, in whom a cause of death was assigned. In the remaining 84% (81/97) of cases, deaths were not due to bacterial superinfection.

The most commonly attributed cause of death was respiratory failure due to COVID-19. Lung superinfections were the cause of death of 3% (16/621) of all patients who underwent postmortem examination, in whom a cause of death was assigned.

This is the first comprehensive review of postmortem studies of persons with COVID-19 for histopathologic evidence of bacterial superinfections. The quality of data on superinfections was uneven, which likely reflected the fact that identifying such events was not a major objective or endpoint in 96% of studies. As such, detailed clinical, microbiologic and histopathologic descriptions of these infections were often lacking, and accompanying discussions were largely cursory.

Histopathologic findings that were consistent with potential lung superinfections were evident in 32% of patients. Lung infections were proven by visualization of bacteria in tissue, microbiologic cultures or PCR in 8% of patients. In 24% of patients, lung superinfections were possible based on histopathologic findings, but causative organisms were not visualized or detected. Potential (i.e., proven or possible) bacterial superinfections included pneumonia (95%), abscesses or empyema (3.5%),

A c c e p t e d M a n u s c r i p t 10 and septic emboli (1.5%). In 73% of pneumonias, histopathologic findings were focal, and, in many instances, they were of uncertain clinical significance (see comments, Table 1 ). When causes of death were assigned, lung superinfections were deemed responsible in only 16% of patients with potential infections and 3% of all SARS-CoV-2-infected patients. Given limitations cited above, the data must be interpreted with caution. Nevertheless, our review indicates that 8%-32% of persons who have died thus far with COVID-19 had superinfections of the lungs, but such infections were uncommonly the cause of death. function that promote pathogenesis of influenza-associated lung infections. [85, 86] It is unclear if DAD or immune system derangements caused by SARS-CoV-2 are also predisposing conditions for secondary pneumonia, or if these infections stem from risks associated with hospitalization or serious illnesses in general. [15] In most reports included in our review, superimposed pneumonia was observed in association with COVID19-associated DAD. The intra-alveolar and peribronchial neutrophilic infiltrates characteristic of bacterial pneumonia are typically more extensive than observed during acute DAD, which usually exhibits diffuse, but less intense interstitial and mild intra-alveolar neutrophil accumulations. [8, 9] Despite these distinctions, it was often difficult to distinguish between DAD complicated by a possible superimposed pneumonia and DAD that reflected the natural course of SARS-CoV-2 infection. [20] In keeping with histopathologic findings, transcriptional profiling of postmortem lung samples from patients with COVID-19 revealed enrichment of genes involved in neutrophil activation and neutrophil-mediated immunity, including those contributing to generation of neutrophil extracellular traps (NETs). [88] NETs may be induced by bacterial-derived mediators, but they are well described in COVID-19 autopsies in the absence of lung superinfections. [50] Pulmonary neutrophilia may also be attributable to chemoattractant properties of complement deposition, which can be another histopathologic feature of COVID-19. [37] We acknowledge that postmortem studies face inherent biases due to the selection of fatal cases, including potential for over-representation of severe pathology and descriptions of histopathologic and microbiologic patterns that may differ from those observed in disease survivors. [4, 51] Our review was limited to bacterial lung infections because they are the most common superinfections in AMR is unclear. [87] However, it is reasonable to assume that microbiology and susceptibility patterns will be in keeping with local epidemiology, and that trends of emerging AMR pathogens (such as increasing prevalence of extended betalactamase-producing Enterobacteriaceae in the United States) will continue. [1] Conclusions.

Postmortem histopathology data indicate that bacterial lung superinfections There was no funding for this study.

Data in this paper were publically available. There was no need for the authors to consent patients.

Dr. Clancy has been awarded investigator-initiated research grants from Astellas, Autopsies, pts from US, dates unclear. "Acute bronchopneumonia" cause of death in 7/8. "While acute bronchopneumonia is usually caused by bacterial infection, it might be possible this particular virus elicits an acute bronchopneumonia pattern, especially in cases that are negative by culture…Negative cultures in cases might also be due to sampling as cultures were taken from periphery of the lungs before they were perfused with formalin and sectioned" Cases were seen with and without DAD. M a n u s c r i p t 24 tazo as prophylaxis"

"Superinfections with Pseudomonas" diagnosed antemortem in 3/7 cases. COVID-19 considered cause of death in most pts.

*In other postmortem studies that examined the lungs (n=30 studies, 85 patients), there were no histopathologic findings described that were consistent with superimposed pneumonia [25, 44, . Therefore, histopathologic findings consistent with superimposed pneumonia were reported in 32% ( Streptoococcus spp., 3

COVID-19, superinfections and antimicrobial development: What can we expect?

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

The role of postmortem studies in pneumonia etiology research

Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness

The spectrum of pathological findings in coronavirus disease (COVID-19) and the pathogenesis of SARS-CoV-2

Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases

Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies

The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

COVID-19 Autopsies

Postmortem examination of three SARS-CoV-2-positive autopsies including histopathologic and immunohistochemical analysis

Histopathological features of multiorgan percutaneous tissue core biopsy in patients with COVID-19

Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center

Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage

Analysis of cardiopulmonary findings in COVID-19 fatalities: High incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia

Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients

A Japanese case of COVID-19: An autopsy report

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Case 23-2020: A 76-Year-Old Woman Who Died from Covid-19

Report: Adrenal Pathology Findings in Severe COVID-19: An Autopsy Study

COVID-19 autopsy in people who died in community settings: the first series

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Gross and histopathological pulmonary findings in a COVID-19 associated death during self-isolation

Postmortem Examination of Patients With COVID-19

Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD

Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Inside the lungs of COVID-19 disease

Pathological Findings of Postmortem Biopsies From Lung, Heart, and Liver of 7 Deceased COVID-19 Patients

Molecular Detection of SARS-CoV-2 Infection in FFPE Samples and Histopathologic Findings in Fatal SARS-CoV-2 Cases

Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities

COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy

Forty Postmortem Examinations in COVID-19 Patients

Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report

The Spectrum of Histopathologic Findings in Lungs of Patients with Fatal COVID-19 Infection

Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge

Pathological Post Mortem Findings in Lungs Infected With Sars-Cov 2

Progression to Fibrosing Diffuse Alveolar Damage in a Series

Increased number of pulmonary megakaryocytes in COVID-19 patients with diffuse alveolar damage: an autopsy study with clinical correlation and review of the literature

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients

Atypical Endovascular Cells in SARS-CoV-2 Pneumonia

The Pathology of Severe COVID-19-Related Lung Damage

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Endothelial cell infection and endotheliitis in COVID-19

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Postmortem Lung Findings in a Patient With Asthma and Coronavirus Disease

Evidence for systematic autopsies in COVID-19 positive deceased: Case report of the first German investigated COVID-19 death

Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations

Preliminary Post-Mortem COVID-19 Evidence of Endothelial Injury and Factor VIII Hyperexpression

Fatal pulmonary fibrosis: a post-COVID-19 autopsy case

SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis

The first COVID-19 autopsy in Spain performed during the early stages of the pandemic

Autopsy findings from the first known death from Severe Acute Respiratory Syndrome SARS-CoV-2 in Spain

SARS-CoV-2-related deaths in routine forensic autopsy practice: histopathological patterns

Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients

Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)

Clinicopathologic and Immunohistochemical Findings from Autopsy of Patient with COVID-19

COVID-19 in a Hispanic Woman

Fatal Pulmonary Thromboembolism in SARS-CoV-2-Infection

Germany's first COVID-19 deceased: a 59-year-old man presenting with diffuse alveolar damage due to SARS-CoV-2 infection

Two Sorts of Microthrombi in a Patient With Coronavirus Disease 2019 and Lung Cancer

Immunostaining in the Lung of a Patient With COVID-19

Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection

COVID-19: Postmortem Diagnostic and Biosafety Considerations

Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients

Post-Mortem Findings in Italian Patients with COVID-19 -a Descriptive Full Autopsy Study of cases with and without co-morbidities

Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature

Presence of hyaluronan in lung alveoli in severe Covid-19 -an opening for new treatment options

Endothelial Dysfunction and Thrombosis in Patients With COVID-19-Brief Report

Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series

Antibiotic consumption and stewardship at a hospital outside of an early Coronavirus disease 2019 epicentre

Clinicopathologic study of thirty-three fatal cases of Asian influenza

Insights into the interaction between influenza virus and pneumococcus

The immunology of influenza virus-associated bacterial pneumonia

PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates

Transcriptional and proteomic insights into the host response in fatal COVID-19 cases

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report